smithkline beecham anglous pharmaceuticals consumer products group create partnership marion merrell dow develop market overthecounter otc nonprescription medicines us the new group would sales last year dollars 660m pounds 3455m operating profits dollars 120m making fifth largest otc group us smithkline beechams shares closed 7p 455p smithkline beecham initially 90 per cent marion merrell dow 10 per cent partnership smithkline beechams american otc sales last year dollars 550m marion merrell dows dollars 111m the aim 5050 arrangement new products licensed the companies said committed similar cooperation countries mr john ziegler north american president smithkline beecham consumer brands lead partnership mr bob bauman anglous groups chief executive said when smithkline beecham created said vision achieve leadership healthcare four business segments he added partnership marion merrell dow another step towards achieving goal both groups prescription products could marketed new group smithkline beecham asked us food drug administration fda otc licence tagamet antiulcer drug whose patents run 1994 it worldwide sales last year dollars 1bn marion merrell dow said might seek otc licences seldane antihistamine antismoking products nicorette nicoderm nicoderm uses transdermal patch launched 1991 sales dollars 137m first six months year the deal rather imprecise said mr jonathan de pass pharmaceuticals analyst bzw it depends whether receive fda approval seldane tagamet whether successfully extend relationship worldwide if implications enormous safety concerns new partnerships seldane tagamet may delay prevent fda approval seldane potentially dangerous patients damaged liver taking two drugs ketoconazole antifungal treatment erythromycin antibiotic there also fears patients stomach cancer could misdiagnose ulcer buy tagamet